Premium
Recent developments and highlights in allergen immunotherapy
Author(s) -
Pfaar Oliver,
Lou Hongfei,
Zhang Yuan,
Klimek Ludger,
Zhang Luo
Publication year - 2018
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13652
Subject(s) - medicine , allergen immunotherapy , clinical trial , position paper , sublingual immunotherapy , intensive care medicine , allergy , immunotherapy , intoxicative inhalant , clinical practice , allergen , immunology , immune system , family medicine , pathology , toxicology , biology
Allergen immunotherapy (AIT) is the only disease‐modifying treatment option for patients with IgE‐mediated inhalant allergies. Though used in clinical practice for more than 100 years, most innovations in AIT efficacy and safety have been developed in the last two decades. This expert review aimed to highlight the recent progress in AIT for both application routes, the sublingual (SLIT) and subcutaneous (SCIT) forms. As such, it covers recent aspects regarding efficacy and safety in clinical trials and real‐life data and outlines new concepts in consensus and position papers as well as in guidelines for AIT. Potential clinical and nonclinical biomarkers are discussed. This review also focuses on potential future perspectives in AIT, such as alternative application routes, immune‐modulating adjuvants, and recombinant vaccines. In conclusion, this state of the art review provides a comprehensive overview of AIT and highlights unmet needs for the future.